NeuClone is a clinical stage biopharmaceutical company exclusively developing and commercialising high quality biosimilar products. Led by a team of industry veterans, we are focused on creating a deep pipeline of high quality biosimilars at the scale and price to meet demand in both new and established markets globally. NeuClone is differentiated by our deep and unmatched pipeline, as well as our Right From the Start® approach where we continually confirm biosimilarity at the earliest stages and throughout development.
View Top Employees from NeuClone| Website | http://neuclone.com |
| Revenue | $6 million |
| Employees | 18 (18 on RocketReach) |
| Founded | 2007 |
| Address | 4 Cornwallis St, Sydney, New South Wales, AU |
| Phone | +61 2 9209 4020 |
| Technologies |
JavaScript,
HTML,
PHP
+7 more
(view full list)
|
| Industry | Pharmaceutical Manufacturing, Business Services General, Biotechnology, Business Services, Science and Engineering, Medical, Health Care, Pharmaceutical |
| Web Rank | 17 Million |
| Keywords | Neuclone |
| Competitors | Alvotech, Bio-Thera Solutions, Formycon AG, Trevena Inc, Xbrane Biopharma AB |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 54171 Companies, NAICS Code 541 Companies, NAICS Code 541713 Companies, NAICS Code 5417 Companies, NAICS Code 54 Companies |
Looking for a particular NeuClone employee's phone or email?
NeuClone Questions
The NeuClone annual revenue was $6 million in 2024.
John Oksinski is the Head of Global Business Development and Alliances of NeuClone.
18 people are employed at NeuClone.
NeuClone is based in Sydney, New South Wales.
The NAICS codes for NeuClone are [54171, 541, 541713, 5417, 54].
The SIC codes for NeuClone are [873, 87].
Top NeuClone Employees
-
11
-
1
-
21
-
25
-
-
2
-
1
Related Companies
